# US 2002/0165266 A1 · Use of oxandrolone in the treatment of burns and other wounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2002/0165266 A1 - Document ID: US20020165266A1 - Status: Published application - Kind: A1 - Application number: 10/011,377 - Filed: 2001-10-22 - Published: 2002-11-07 - Earliest claimed: 1996-12-05 - Assignees: Bio-Technology General Corp. - Inventors: Don Fishbein - Web page: https://patentgrep.com/patent/US20020165266A1 ## CPC - A61K 31/366: having six-membered rings, e.g. delta-lactones - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient. ## Claims ### Claim 1 A method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. ### Claim 2 A method of improving the rate of healing of a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. ### Claim 3 (depends on 1, 2) A method according to claims 1 or 2, wherein the wound is a burn wound. ### Claim 4 (depends on 1, 2) A method according to claims 1 or 2, wherein the wound comprises an ulcer. ### Claim 5 (depends on 1, 2) A method according to claims 1 or 2, wherein the wound comprises a skin graft. ### Claim 6 (depends on 1, 2) A method according to claims 1 or 2 wherein the amount of the oxandrolone is about 1-100 mg per day. ### Claim 7 (depends on 6) A method according to claim 6 wherein the amount of the oxandrolone is about 20 mg per day. ### Claim 8 (depends on 6) A method according to claim 6 wherein the amount of the oxandrolone is about 80 mg per day. ### Claim 9 (depends on 1, 2) A method according to claims 1 or 2 wherein the oxandrolone is administered orally. ### Claim 10 (depends on 1, 2) A method according to claims 1 or 2 wherein the oxandrolone is administered topically. ### Claim 11 (depends on 1, 2) A method according to claims 1 or 2 wherein the oxandrolone is injected. ### Claim 12 (depends on 1, 2) A method according to claims 1 or 2 wherein the oxandrolone is in a solid dosage form. ### Claim 13 (depends on 1, 2) A method according to claims 1 or 2 wherein the oxandrolone is in a liquid dosage form. ### Claim 14 (depends on 1, 2) A method according to claims 1 or 2 wherein the oxandrolone is in a sustained-release formulation. ### Claim 15 A method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. ### Claim 16 A method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient. ### Claim 17 (depends on 15, 16) A method according to claims 15 or 16 wherein the amount of the oxandrolone is about 1-100 mg per day. ### Claim 18 (depends on 17) A method according to claim 17 wherein the amount of the oxandrolone is about 20 mg per day. ### Claim 19 (depends on 17) A method according to claim 17 wherein the amount of the oxandrolone is about 80 mg per day. ### Claim 20 (depends on 15, 16) A method according to claims 15 or 16 wherein the oxandrolone is administered orally. ### Claim 21 (depends on 15, 16) A method according to claims 15 or 16 wherein the oxandrolone is administered topically. ### Claim 22 (depends on 15, 16) A method according to claims 15 or 16 wherein the oxandrolone is injected. ### Claim 23 (depends on 15, 16) A method according to claims 15 or 16 wherein the oxandrolone is in a solid dosage form. ### Claim 24 (depends on 15, 16) A method according to claims 15 or 16 wherein the oxandrolone is in a liquid dosage form. ### Claim 25 (depends on 15, 16) A method according to claims 15 or 16 wherein the oxandrolone is in a sustained-release formulation. ### Claim 26 A composition for use in topical treatment of wounds which comprises an oxandrolone and a pharmaceutically acceptable carrier. ### Claim 27 (depends on 26) A composition according to claim 26 wherein the wound is selected from the group consisting of a burn, an ulcer and a skin graft. ### Claim 28 (depends on 1, 2, 15, 16) A method according to claims 1, 2, 15 or 16, wherein the oxandrolone is 17α-methyl-17β-hydroxy-2-oxa-5α-androstan-3-one. ### Claim 29 (depends on 4) A method according to claim 4 wherein the ulcer is a decubitus ulcer.